๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed/Refractory Multiple Myeloma (MM)

Universal CAR-T Cell Therapy for MM NCT07248176NA1 site๐Ÿ“ Shanghai Bioray Laboratories ยท Tests: Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study NCT06271252Phase 11 site๐Ÿ“ Atlanta OriCell Therapeutics Co., Ltd. ยท Tests: OriCAR-017 Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma NCT07333430Phase 11 site๐Ÿ“ Jerusalem Hadassah Medical Organization ยท Tests: Naive HBI0101 CAR-T A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma NCT07637578Phase 26 sites๐Ÿ“ Denver๐Ÿ“ Denver๐Ÿ“ Columbia SCRI Development Innovations, LLC ยท Tests: Elranatamab, Tocilizumab Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma NCT05972135Phase 217 sites๐Ÿ“ Tucson๐Ÿ“ Denver๐Ÿ“ Denver SCRI Development Innovations, LLC ยท Tests: Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma NCT07116616Phase 1, Phase 210 sites๐Ÿ“ Birmingham๐Ÿ“ San Francisco๐Ÿ“ Atlanta ModernaTX, Inc. ยท Tests: mRNA-2808 Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003555Phase 11 site๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Dual-targeting BCMA-CD19 CAR-T cell infusion MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) NCT06152575Phase 3270 sites๐Ÿ“ Mobile๐Ÿ“ Goodyear๐Ÿ“ Beverly Hills Pfizer ยท Tests: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM NCT07377435Phase 11 site๐Ÿ“ Boston David Avigan ยท Tests: DC/MM Fusion Vaccine, GM-CSF Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM NCT06518551Phase 1, Phase 23 sites๐Ÿ“ Boston๐Ÿ“ Boston๐Ÿ“ Boston Omar Nadeem, MD ยท Tests: Elotuzumab, Iberdomide, Dexamethasone Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003568Phase 11 site๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Dual-targeting BCMA-GPRC5D CAR-T cell infusion A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site๐Ÿ“ Camden Roger Strair ยท Tests: Soursop tea Human BCMA Targeted T Cells Injection๏ผˆBCMA CAR-T๏ผ‰for Subjects With R/R MM NCT05594797Phase 22 sites๐Ÿ“ Shanghai๐Ÿ“ Wenzhou Hrain Biotechnology Co., Ltd. ยท Tests: Human BCMA Targeted T Cells Injection Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) NCT06759181Phase 1, Phase 21 site๐Ÿ“ Xuzhou Xuzhou Medical University ยท Tests: anti-BCMA/FcRL5 CAR T A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects NCT07280013Phase 119 sites๐Ÿ“ Gilbert๐Ÿ“ Sacramento๐Ÿ“ Santa Monica C4 Therapeutics, Inc. ยท Tests: Cemsidomide, Elranatamab A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites๐Ÿ“ Santander๐Ÿ“ Salamanca๐Ÿ“ Barcelona IDP Discovery Pharma S.L. ยท Tests: IDP-121 A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma NCT06115135Phase 22 sites๐Ÿ“ West Hollywood๐Ÿ“ Omaha Oncotherapeutics ยท Tests: Venetoclax Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma NCT06645678Phase 1, Phase 27 sites๐Ÿ“ Singapore๐Ÿ“ Singapore๐Ÿ“ Hwasun YOUNGIL KOH ยท Tests: Elranatamab, Mezigdomide, Dexamethasone A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma NCT06799026Phase 12 sites๐Ÿ“ Boston๐Ÿ“ Boston David Avigan ยท Tests: Elranatamab, GM-CSF, DC/MM Fusion Vaccine Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) NCT06196255Phase 1, Phase 21 site๐Ÿ“ Xuzhou Xuzhou Medical University ยท Tests: anti-FcRL5 CAR-T Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM NCT06515262NA1 site๐Ÿ“ Kunming 920th Hospital of Joint Logistics Support Force of People'sโ€ฆ ยท Tests: Anti-BCMA-GPRC5D CAR-T cells infusion All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma NCT06158412Phase 21 site๐Ÿ“ Xiamen The First Affiliated Hospital of Xiamen University ยท Tests: All-trans Retinoic Acid in combination with the KPD Regimen To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL NCT06045091EARLY Phase 11 site๐Ÿ“ Shanghai Hrain Biotechnology Co., Ltd. ยท Tests: Human BCMA targeted CAR-NK cells injection Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma NCT07725406Phase 11 site๐Ÿ“ New York Weill Medical College of Cornell University ยท Tests: Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapโ€ฆ A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. NCT07429721EARLY Phase 11 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: QI-019A Injection Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. NCT04771572Phase 18 sites๐Ÿ“ Chicago๐Ÿ“ Boston๐Ÿ“ Chapel Hill Newave Pharmaceutical Inc ยท Tests: LP-118 A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) NCT07409246Phase 114 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ Denver AbbVie ยท Tests: ABBV-438 Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma NCT07139509Phase 11 site๐Ÿ“ Xiโ€™an Xi'an No.3 Hospital ยท Tests: allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells ELISA in Relapsed/Refractory MM NCT06832865Phase 23 sites๐Ÿ“ Boston๐Ÿ“ Boston๐Ÿ“ Boston Massachusetts General Hospital ยท Tests: elranatamab, Isatuximab SC, Isatuximab SC-OBDS Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy